Exhibit 99.1 Leap Therapeutics Reports First Quarter 2024 Financial Results Cambridge, MA – May 13, 2024 – Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the first quarter ended March 31, 2024. Leap Highlights: "We appreciate the strong support of Gilead and the new and existing institutional investors who participated in our recent $40 million financing that will enable the expansion and co ...

Drug Development - The company is developing investigational drugs DKN-01 and FL-301, which are currently undergoing clinical trials and have not yet been approved by the FDA[12] - The company anticipates potential market opportunities for DKN-01 and FL-301, with ongoing collaborations with BeiGene, NovaRock, and Adimab to enhance development efforts[8] - The company is focused on the timing and results of its preclinical studies and clinical trials, which are critical for the advancement of its product candidates[8] - The company acknowledges various risks and uncertainties that could impact its future performance, including competition and regulatory approval timelines[9] - The company is aware of potential delays in clinical trials and manufacturing due to global conflicts or supply chain issues[9] Financial Considerations - The company is assessing its capital requirements and may seek additional financing to support its product development plans[8] - The company has not provided specific revenue figures for the quarter, but it emphasizes the importance of market acceptance for its investigational products[8] - The company has not disclosed specific financial results in this report, but it emphasizes the need for careful monitoring of its financial condition and liquidity[9] - The company has not provided specific guidance for future earnings or revenue, highlighting the uncertainty in the current market environment[9] Intellectual Property - The company is committed to maintaining and protecting its intellectual property rights as part of its growth strategy[8]

Exhibit 99.1 Leap Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results Cambridge, MA – March 18, 2024 – Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the fourth quarter and year ended December 31, 2023. Leap Highlights: "As we reflect on the fourth quarter and the achievements of the past year, we are proud of the strides we've made in advancing DKN- 01 and integrating o ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-37990 LEAP THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware State or other jurisd ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37990 LEAP THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware State or other ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37990 LEAP THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware State or other juris ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37990 LEAP THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) 27-4412575 (I.R.S. Employer ...

Table of Contents Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes ☐ No ☒ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file num ...

DKN-01 Clinical Development - DKN-01 exhibits single-agent activity in three indications and is being explored in combinations with checkpoint inhibitors and chemotherapy[4, 13] - In first-line GEJ/GC, DKN-01 combined with tislelizumab and chemotherapy showed a 68% overall response rate (ORR) in the mITT population[21, 64] - In DKK1-high patients within the first-line GEJ/GC study, the ORR reached 90% with DKN-01, tislelizumab, and chemotherapy, and a median PFS of 113 months was observed[21, 23, 29, 64] - In second-line GEJ/GC, DKN-01 plus tislelizumab demonstrated a 27% ORR and 43% disease control rate (DCR) in anti-PD-1/PD-L1-naïve mITT patients[32] - In second-line GEJ/GC DKK1-high/PD-L1 vCPS ≥ 10 patients, DKN-01 plus tislelizumab achieved a 55% ORR and 73% DCR[32, 36] - DKN-01 monotherapy in 2L+ EEC showed a 25% ORR and 63% clinical benefit in DKK1-high patients, with a median PFS of 43 months compared to 18 months in DKK1-low patients[78, 82] Strategic Partnership with BeiGene - Leap Therapeutics has a strategic partnership with BeiGene, including a potential $10 million option exercise fee based on data from DKN-01 plus tislelizumab combination studies in gastric cancer[15] - The total potential option exercise, clinical, regulatory, and commercial milestones could reach $132 million[15] - Total payments to date from BeiGene amount to $1525 million, comprising a $3 million option fee and a $1225 million equity investment[15] Colorectal Cancer Development - Preclinical data suggests DKN-01 has additive activity with 5-FU chemotherapy and can overcome 5-FU resistance in colorectal cancer models[65, 68, 70] - DKN-01 also shows additive activity with anti-PD-1 antibodies in colorectal cancer models[65, 72]

For the transition period from to Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-37990 LEAP THERAPEUTICS, INC. 27-4412575 (I.R.S. Employer Identification No.) 47 Thorndike St, Suite B1-1, Ca ...